Exelixis Partners with Sairopa to Enhance Cancer Immunotherapy Development

Exelixis Partners with Sairopa to Advance Immunotherapy Research

Exelixis, Inc. collaborates with Sairopa B.V. in a noteworthy clinical development agreement focused on ADU-1805, a novel anti-SIRPα antibody designed to enhance the immune response against cancer. This partnership marks a significant step in the field of immunotherapy, with Exelixis securing an exclusive option for worldwide licensing rights to ADU-1805, contingent upon the evaluation of ongoing phase 1 clinical study data. The collaboration underscores Exelixis's commitment to pioneering innovative cancer treatments, leveraging Sairopa's cutting-edge research capabilities in the immuno-oncology space.

The financial aspects of the agreement reflect the depth of commitment between the two companies. Exelixis has already provided substantial funding, beginning with an upfront payment of $40 million. Subsequent payments include a $35 million milestone tied to the Investigational New Drug (IND) clearance from the FDA and an additional $35 million linked to future clinical development milestones. This financial backing not only facilitates the ongoing phase 1 study, which evaluates the safety and pharmacokinetics of ADU-1805 across multiple centers in the U.S. and Europe, but also highlights the strategic alignment between Exelixis and Sairopa in advancing next-generation cancer therapies.

Patient enrollment for the phase 1 study includes both monotherapy and combination therapy approaches, notably with pembrolizumab, a well-established checkpoint inhibitor. The collaboration aims to deliver breakthrough cancer treatments, with Sairopa's pipeline also featuring ADU-1604, an anti-CTLA4 antibody, and a bispecific antibody targeting both SIRPα and PD-L1. Looking ahead, Sairopa plans to initiate a phase 2 trial in 2025 and file an IND for the bispecific antibody in 2026, indicating a robust strategy for expanding its immunotherapy offerings. This partnership not only enhances Sairopa's position in the oncology landscape but also aligns with Exelixis's broader mission to improve patient outcomes through innovative therapeutic solutions.

In addition to this partnership, Sairopa's focus on innovative cancer immunotherapies is reflected in its diverse pipeline, which is indicative of a growing trend in the biotechnology sector. The collaboration with Exelixis, a company known for its oncology expertise, positions Sairopa to make substantial contributions to cancer treatment advancements. Together, they aim to leverage their combined strengths to address unmet medical needs in oncology, ultimately striving for improved survival rates and quality of life for cancer patients.

For more information, visit www.sairopa.com.